Sender: |
|
Date: |
Mon, 2 Jun 2003 17:30:43 +0100 |
Reply-To: |
|
Subject: |
|
MIME-Version: |
1.0 |
Content-Transfer-Encoding: |
7bit |
In-Reply-To: |
<001f01c324c6$42708220$21ac58d8@BusyBeeAcres> |
Content-Type: |
text/plain; charset="iso-8859-1" |
From: |
|
Parts/Attachments: |
|
|
Bob said,
"I predict when resistance to Apistan happens you will soon find fault with
thymol. The still effective Apistan treatment (U.K.) is making the thymol
treatment seem more effective in my opinion."
Why?
We already have Apistan resistance in Cornwall and Devon, (Southernmost
England); Apiguard is keeping highly infested hives alive down there by
providing a good control of the resistant mite populations.
Apiguard was initially developed to combat pyrethroid-resistant varroa in
Italy. Apiguard (as well as other thymol-based treatments) have been used
widely in Europe for several years with a reasonable degree of success.
There is no reported resistance to thymol (as yet) and Vita (Europe) Limited
is monitoring this closely. As the mode of action of thymol on mites is
completely different to that of pyrethroids there is no obvious reason for
the two to be linked.
"U.S. tests on Thymol have never produced effiacy in the range claimed by
vita Europe" - maybe, but we are talking about Apiguard, not just thymol.
I'm not saying that Apiguard doesn't have its limitations, it certainly
does, but Apiguard was formulated to improve upon the effect of thymol
alone. Our US data doesn't look too bad at all but we do need to complete
tests across The States to get a better picture.
Max
Dr Max Watkins
Vita (Europe) Limited
21/23 Wote Street
Basingstoke
Hampshire RG21 7NE
UK
Tel.: +44 (0) 1256 473177
Fax: +44 (0) 1256 473179
e-mail: [log in to unmask]
web: http://www.vita-europe.com
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
-- Visit www.honeybeeworld.com/BEE-L for rules, FAQ and other info ---
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
|
|
|